GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jaguar Health Inc (NAS:JAGX) » Definitions » Altman Z-Score

Jaguar Health (Jaguar Health) Altman Z-Score : -9.33 (As of May. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Jaguar Health Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -9.25 is in distress zone. This implies bankruptcy possibility in the next two years.

Jaguar Health has a Altman Z-Score of -9.33, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Jaguar Health's Altman Z-Score or its related term are showing as below:

JAGX' s Altman Z-Score Range Over the Past 10 Years
Min: -10.18   Med: -5.91   Max: 96.89
Current: -9.25

During the past 11 years, Jaguar Health's highest Altman Z-Score was 96.89. The lowest was -10.18. And the median was -5.91.


Jaguar Health Altman Z-Score Historical Data

The historical data trend for Jaguar Health's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jaguar Health Altman Z-Score Chart

Jaguar Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.86 -5.42 -7.40 -10.18 -10.14

Jaguar Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.18 -8.42 -9.68 -10.98 -10.14

Competitive Comparison of Jaguar Health's Altman Z-Score

For the Biotechnology subindustry, Jaguar Health's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jaguar Health's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Jaguar Health's Altman Z-Score falls into.



Jaguar Health Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Jaguar Health's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.2753+1.4*-6.0723+3.3*-0.6997+0.6*1.5975+1.0*0.1923
=-9.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $50.76 Mil.
Total Current Assets was $27.96 Mil.
Total Current Liabilities was $13.99 Mil.
Retained Earnings was $-308.25 Mil.
Pre-Tax Income was -9.309 + -7.904 + -12.291 + -12.397 = $-41.90 Mil.
Interest Expense was -0.248 + -0.5 + -3.453 + -2.181 = $-6.38 Mil.
Revenue was 2.3 + 2.813 + 2.676 + 1.972 = $9.76 Mil.
Market Cap (Today) was $73.27 Mil.
Total Liabilities was $45.87 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(27.963 - 13.987)/50.763
=0.2753

X2=Retained Earnings/Total Assets
=-308.248/50.763
=-6.0723

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-41.901 - -6.382)/50.763
=-0.6997

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=73.271/45.866
=1.5975

X5=Revenue/Total Assets
=9.761/50.763
=0.1923

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Jaguar Health has a Altman Z-Score of -9.33 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Jaguar Health  (NAS:JAGX) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Jaguar Health Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Jaguar Health's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Jaguar Health (Jaguar Health) Business Description

Traded in Other Exchanges
Address
200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments-human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Executives
Anula Jayasuriya director 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022
Pravin R Chaturvedi officer: Chief Scientific Officer C/O JAGUAR HEALTH INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO CA 94104
Lisa A Conte director, officer: CEO & President 213 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Carol R. Lizak officer: Chief Accounting Officer 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
James J Bochnowski director C/O DELPHI VENTURES, 160 BOVET RD, SUITE 408, SAN MATEO CA 94402
Jonathan S. Wolin officer: Chief of Staff, CCO & GC 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Jonathan B. Siegel director C/O KINGDON CAPITAL MANAGEMENT, L.L.C., 152 WEST 57TH STREET, 50TH FLOOR, NEW YORK NY 10019
Bryan Ezralow 1994 Trust Dated December 22, 1994 10 percent owner 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302
Bryan Ezralow 10 percent owner THE EZRALOW CO, LLC, 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302-1549
Nantucket Investments Ltd 10 percent owner PO BOX 282, REGENCY COURT, GLATEGNY ESPLANADE, ST PETER PORT Y7 GY1 3RH
Jonathan M Glaser 10 percent owner 11601 WILSHIRE BLVD., SUITE 2180, LOS ANGELES CA 90025
Murray David Macnaughtan director C/O JAGUAR HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Greg J Divis director 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jeffery C. Johnson director C/O SAGARD CAPITAL PARTNERS, L.P., 280 PARK AVENUE, 3F WEST, STAMFORD CT 06901
Sagard Capital Partners, L.p. 10 percent owner 280 PARK AVENUE, 3RD FLOOR WEST, NEW YORK NY 10017

Jaguar Health (Jaguar Health) Headlines

From GuruFocus